Stockreport

BRIEF-Thomas Clay Reports A 8.3 Pct Stake In Aviragen Therapeutics [Reuters]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF BRIEF-Thomas Clay Reports A 8.3 Pct Stake In Aviragen Therapeutics | Reuters Reuters Staff 1 Min Read Dec 29 (Reuters) - Aviragen Therapeutics Inc: * THOMAS CLAY REPORTS [Read more]